Trust Company of Vermont’s Filana Therapeutics FLNA Stock Holding History

Trust Company of Vermont’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-49	Closed	–	–	1002
2017 Q3	$0	Hold	49	–	–	﹤0.01%	982
2017 Q2	$0	Hold	49	–	–	﹤0.01%	1004
2017 Q1	$0	Hold	49	–	–	﹤0.01%	909
2016 Q4	$0	Hold	49	–	–	﹤0.01%	942
2016 Q3	$0	Hold	49	–	–	﹤0.01%	860
2016 Q2	$1K	Hold	49	–	–	﹤0.01%	832
2016 Q1	$1K	Hold	49	–	–	﹤0.01%	727
2015 Q4	$1K	Hold	49	–	–	﹤0.01%	774
2015 Q3	$1K	Hold	49	–	–	﹤0.01%	779
2015 Q2	$1K	Hold	49	–	–	﹤0.01%	801
2015 Q1	$1K	Hold	49	–	–	﹤0.01%	763
2014 Q4	$1K	Hold	49	–	–	﹤0.01%	798
2014 Q3	$1K	Hold	49	–	–	﹤0.01%	796
2014 Q2	$2K	Hold	49	–	–	﹤0.01%	717
2014 Q1	$2K	Hold	49	–	–	﹤0.01%	717
2013 Q4	$2K	Hold	49	–	–	﹤0.01%	698
2013 Q3	$1K	Hold	49	–	–	﹤0.01%	697
2013 Q2	$1K	Buy	+49	New	+$1.04K	﹤0.01%	690

Other funds holding FLNA

First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Trust Company of Vermont's FLNA Position: Q4 2017 in Review

Trust Company of Vermont sold out of Filana Therapeutics (FLNA) in Q4 2017, closing a stake of 49 shares.

Trust Company of Vermont first reported a position in FLNA in Q2 2013 and held it in 18 quarters. The position peaked at $2K in Q2 2014. 26 funds tracked by Wall St. Rank hold FLNA as of Q4 2017.

Trust Company of Vermont reported no remaining Filana Therapeutics position as of Q4 2017 after selling out during the quarter.
Trust Company of Vermont sold 49 Filana Therapeutics shares in Q4 2017.
Trust Company of Vermont first reported a position in Filana Therapeutics in Q2 2013 and held it in 18 quarters.
Trust Company of Vermont's Filana Therapeutics position peaked at $2K in Q2 2014.
26 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2017.

Based on Trust Company of Vermont's 13F filing for Q4 2017, filed 2 Feb 2018.